TY - JOUR
T1 - COVID-19 and substance use disorders
T2 - Recommendations to a comprehensive healthcare response. an international society of addiction medicine practice and policy interest group position paper
AU - Farhoudian, Ali
AU - Baldacchino, Alexander
AU - Clark, Nicolas
AU - Gerra, Gilberto
AU - Ekhtiari, Hamed
AU - Dom, Geert
AU - Mokri, Azarakhsh
AU - Sadeghi, Mandana
AU - Nematollahi, Pardis
AU - Demasi, Maryanne
AU - Schutz, Christian G.
AU - Hashemian, Seyed Mohammadreza
AU - Tabarsi, Payam
AU - Galea-Singer, Susanna
AU - Carra, Giuseppe
AU - Clausen, Thomas
AU - Kouimtsidis, Christos
AU - Tolomeo, Serenella
AU - Radfar, Seyed Ramin
AU - Razaghi, Emran Mohammad
N1 - Publisher Copyright:
© 2020 Iran University of Medical Sciences. All rights reserved.
PY - 2020/4
Y1 - 2020/4
N2 - Coronavirus Disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations. People Who Use Drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These conditions put them at a higher risk of COVID-19 infection and its complications. In this paper, an international group of experts on addiction medicine, infectious diseases, and disaster psychiatry explore the possible raised concerns in this issue and provide recommendations to manage the comorbidity of COVID-19 and Substance Use Disorder (SUD).
AB - Coronavirus Disease 2019 (COVID-19) is escalating all over the world and has higher morbidities and mortalities in certain vulnerable populations. People Who Use Drugs (PWUD) are a marginalized and stigmatized group with weaker immunity responses, vulnerability to stress, poor health conditions, high-risk behaviors, and lower access to health care services. These conditions put them at a higher risk of COVID-19 infection and its complications. In this paper, an international group of experts on addiction medicine, infectious diseases, and disaster psychiatry explore the possible raised concerns in this issue and provide recommendations to manage the comorbidity of COVID-19 and Substance Use Disorder (SUD).
KW - Addiction medicine
KW - Coronavirus
KW - Coronavirus Disease 2019 (COVID-19)
KW - Harm reduction
KW - Methadone
KW - Opioid substitution therapy
KW - Pandemic
KW - Policy
KW - Public health
KW - Substance use disorder
UR - https://www.scopus.com/pages/publications/85085038286
UR - https://www.scopus.com/pages/publications/85085038286#tab=citedBy
U2 - 10.32598/bcn.11.covid19.1
DO - 10.32598/bcn.11.covid19.1
M3 - Review article
AN - SCOPUS:85085038286
SN - 2008-126X
VL - 11
SP - 133
EP - 150
JO - Basic and Clinical Neuroscience
JF - Basic and Clinical Neuroscience
IS - 2
ER -
